Drug Formulary Review Archives – December 1, 2006
December 1, 2006
View Archives Issues
-
Technology helps combat pharmacist shortage
Faced with the realization in the early years of this decade that 26 community pharmacies had recently closed and 12 more were at risk of closing, the North Dakota Board of Pharmacy started looking for a solution. -
Study: Adverse drug events cause ED visits
Some 700,000 U.S. residents go to hospital emergency departments (EDs) each year because of adverse drug events (ADE), according to research reported in the Oct. 18 issue of the Journal of the American Medical Association. One-sixth of those ED visits led to hospitalization of the patient in an inpatient care unit or ED observation bed. -
Nicotine replacement may hurt ICU patients
Mayo Clinics researchers say smokers admitted to intensive care units appear to be at higher risk of cardiovascular events and death if they are given nicotine replacement therapy to ameliorate acute nicotine withdrawal. The researchers presented their findings at the annual meeting of the American College of Chest Physicians. -
Pharmacists' role in critical pathway development
Pharmacists using new technology, new knowledge, and evidence-based medicine approaches can and should play a critical role in answering questions about the value of critical pathways, according to members of the 2005 American College of Clinical Pharmacy (ACCP) Task Force on Critical Pathways. -
New FDA Approvals
FDA recently approved these drugs: Pantheon's Zolinza (vorinostat) capsules were approved for treating cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. -
Drug Criteria & Outcomes: Iplex® and Increlex® Formulary Evaluation
Iplex® (mecasermin rinfabate) and Increlex® (mecasermine) are two recently approved agents for the treatment of short stature in pediatric patients. Mecasermin rinfabate is composed of human insulin-like growth factor-1 (IGF-1) and human insulin-like growth factor-binding protein-3 (IGFBP-3). -
Drug Criteria & Outcomes: MTM: Another New Pharmacy Acronym?
Medications taken incorrectly in the United States represent annual costs of more than $100 billion.